Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism

2000, Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association, Am J Psychiatry, 157, 1 Movig, 2003, Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients, Arch Intern Med, 163, 2354, 10.1001/archinte.163.19.2354 Sewnath, 2002, Increased perioperative blood loss during treatment with paroxetine, Ned Tijdschr Geneeskd, 146, 1800 Ceylan, 2005, Bleeding induced by SSRIs, Eur Psychiatry, 20, 570, 10.1016/j.eurpsy.2004.09.018 Linnebur, 2002, Venlafaxine‐associated vaginal bleeding, Pharmacotherapy, 22, 652, 10.1592/phco.22.8.652.33219 Lake, 2000, Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence, J Child Adolesc Psychopharmacol, 10, 35, 10.1089/cap.2000.10.35 De Abajo, 2006, Antidepressants and risk of upper gastrointestinal bleeding, Basic Clin Pharmacol Toxicol, 98, 304, 10.1111/j.1742-7843.2006.pto_303.x Wessinger, 2006, Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis, Aliment Pharmacol Ther, 23, 937, 10.1111/j.1365-2036.2006.02859.x Meijer, 2004, Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants, Arch Intern Med, 164, 2367, 10.1001/archinte.164.21.2367 Dalton, 2003, Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population‐based cohort study, Arch Intern Med, 163, 59, 10.1001/archinte.163.1.59 De Abajo, 1999, Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case‐control study, BMJ, 319, 1106, 10.1136/bmj.319.7217.1106 Serebruany, 2006, Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?, Am J Med, 119, 113, 10.1016/j.amjmed.2005.03.044 Schalekamp, 2008, Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins, Arch Intern Med, 168, 180, 10.1001/archinternmed.2007.32 Laine‐Cessac, 1998, Study of haemostasis in depressive patients treated with fluoxetine, Pharmacoepidemiol Drug Saf, 7, S54, 10.1002/(SICI)1099-1557(199808)7:1+<S54::AID-PDS345>3.0.CO;2-Z Hergovich, 2000, Paroxetine decreases platelet serotonin storage and platelet function in human beings, Clin Pharmacol Ther, 68, 435, 10.1067/mcp.2000.110456 Markovitz, 2000, Platelet activation in depression and effects of sertraline treatment: An open‐label study, Am J Psychiatry, 157, 1006, 10.1176/appi.ajp.157.6.1006 Serebruany, 2001, Platelet inhibition by sertraline and N‐desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors, Pharmacol Res, 43, 453, 10.1006/phrs.2001.0817 Pollock, 2000, Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment, J Clin Psychopharmacol, 20, 137, 10.1097/00004714-200004000-00004 Musselman, 2000, Platelet reactivity in depressed patients treated with paroxetine: preliminary findings, Arch Gen Psychiatry, 57, 875, 10.1001/archpsyc.57.9.875 Skop, 1996, Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors, Psychosomatics, 37, 12, 10.1016/S0033-3182(96)71592-X Lesch, 2005, Pharmacogenetics of the serotonin transporter, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1062, 10.1016/j.pnpbp.2005.03.012 Murphy, 2004, Serotonin transporter: gene, genetic disorders, and pharmacogenetics, Mol Interv, 4, 109, 10.1124/mi.4.2.8 Hu, 2006, Serotonin transporter promoter gain‐of‐function genotypes are linked to obsessive‐compulsive disorder, Am J Hum Genet, 78, 815, 10.1086/503850 Hu, 2007, Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression, Arch Gen Psychiatry, 64, 783, 10.1001/archpsyc.64.7.783 Alderman, 1996, Effects of serotonin reuptake inhibitors on hemostasis, Ann Pharmacother, 30, 1232, 10.1177/106002809603001103 McCloskey, 2008, Selective serotonin reuptake inhibitors: measurement of effect on platelet function, Transl Res, 151, 168, 10.1016/j.trsl.2007.10.004 Hougardy, 2008, Serotonin transporter polymorphism and bleeding time during SSRI therapy, Br J Clin Pharmacol, 65, 761, 10.1111/j.1365-2125.2008.03098.x Tosetto, 2006, A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD), J Thromb Haemost, 4, 766, 10.1111/j.1538-7836.2006.01847.x Dean, 2007, Generalized linear mixed models: a review and some extensions, Lifetime Data Anal, 13, 497, 10.1007/s10985-007-9065-x Ruhe, 2008, Evidence why dose‐escalation of paroxetine in major depressive disorder is not effective: A 6‐week, randomized‐controlled trial with assessment of serotonin transporter occupancy, Neuropsychopharmacology Sarma, 2006, Venlafaxine‐induced ecchymoses and impaired platelet aggregation, Eur J Haematol, 77, 533, 10.1111/j.0902-4441.2006.t01-1-EJH2919.x Murphy, 2008, Targeting the murine serotonin transporter: insights into human neurobiology, Nat Rev Neurosci, 9, 85, 10.1038/nrn2284 Carneiro, 2008, Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans, J Clin Invest, 118, 1544, 10.1172/JCI33374 Schreijer, 2006, Activation of coagulation system during air travel: a crossover study, Lancet, 367, 832, 10.1016/S0140-6736(06)68339-6 Owens, 1997, Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites, J Pharmacol Exp Ther, 283, 1305